Pharma Avanti: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Pharma Avanti
Largest movements
- Cash -€142,403
down €142,403 (-98.4%), from €144,692 to €2,289
mainly Other debts (-€175,918) and Deferred charges and accrued income (-€1,364)
- Tangible fixed assets -€25,406
down €25,406 (-26.6%), from €95,587 to €70,181
- Other debts -€175,918
down €175,918 (-16.4%), from €1.1m to €894,002
- Gross operating margin +€13,793
up €13,793 (+25.5%), from €54,175 to €67,968
- Depreciation +€12,234
up €12,234 (+92.9%), from €13,172 to €25,406
- Taxes +€1,435
up €1,435 (+163%), from €883 to €2,318
- Financial charges -€830
down €830 (-2.3%), from €36,559 to €35,729
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €2,243,897 | €2,076,095 | -€167,801 | -7.5% |
| Fixed assets | 21/28 | €2,095,588 | €2,070,182 | -€25,406 | -1.2% |
| Tangible fixed assets | 22/27 | €95,587 | €70,181 | -€25,406 | -26.6% |
| Furniture and vehicles | 24 | €95,587 | €70,181 | -€25,406 | -26.6% |
| Financial fixed assets | 28 | €2,000,002 | €2,000,002 | = | 0.0% |
| Current assets | 29/58 | €148,308 | €5,913 | -€142,395 | -96.0% |
| Amounts receivable within one year | 40/41 | €1,620 | €263 | -€1,357 | -83.8% |
| Other amounts receivable | 41 | €1,620 | €263 | -€1,357 | -83.8% |
| Cash at bank and in hand | 54/58 | €144,692 | €2,289 | -€142,403 | -98.4% |
| Deferred charges and accrued income | 490/1 | €1,997 | €3,361 | +€1,364 | +68.3% |
| Total equity and liabilities | 10/49 | €2,243,897 | €2,076,095 | -€167,801 | -7.5% |
| Equity | 10/15 | €1,145,480 | €1,147,849 | +€2,369 | +0.2% |
| Contributions | 10/11 | €616,000 | €616,000 | = | 0.0% |
| Reserves | 13 | €529,480 | €531,849 | +€2,369 | +0.4% |
| Distributable reserves | 133 | €529,480 | €531,849 | +€2,369 | +0.4% |
| Amounts payable | 17/49 | €1,098,417 | €928,246 | -€170,170 | -15.5% |
| Amounts payable within one year | 42/48 | €1,098,417 | €928,246 | -€170,170 | -15.5% |
| Trade debts | 44 | €6,588 | €6,408 | -€180 | -2.7% |
| Suppliers | 440/4 | €6,588 | €6,408 | -€180 | -2.7% |
| Taxes, remuneration and social security | 45 | €21,909 | €27,837 | +€5,928 | +27.1% |
| Taxes | 450/3 | €15,290 | €17,828 | +€2,538 | +16.6% |
| Remuneration and social security | 454/9 | €6,619 | €10,009 | +€3,390 | +51.2% |
| Other amounts payable | 47/48 | €1,069,920 | €894,002 | -€175,918 | -16.4% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €13,172 | €25,406 | +€12,234 | +92.9% |
| Other operating charges | 640/8 | €1,759 | €2,146 | +€387 | +22.0% |
| Gross operating margin | 9900 | €54,175 | €67,968 | +€13,793 | +25.5% |
| Operating profit (loss) | 9901 | €39,243 | €40,415 | +€1,172 | +3.0% |
| Financial income | 75/76B | - | €1 | +€1 | |
| Recurring financial income | 75 | - | €1 | +€1 | |
| Financial charges | 65/66B | €36,559 | €35,729 | -€830 | -2.3% |
| Recurring financial charges | 65 | €36,559 | €35,729 | -€830 | -2.3% |
| Profit (loss) for the period before taxes | 9903 | €2,684 | €4,687 | +€2,003 | +74.6% |
| Income taxes | 67/77 | €883 | €2,318 | +€1,435 | +163% |
| Profit (loss) for the period | 9904 | €1,801 | €2,369 | +€568 | +31.5% |
| Profit (loss) for the period to be appropriated | 9905 | €1,801 | €2,369 | +€568 | +31.5% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 26 October 2026 via checked.be.